Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?

Miguel-Angel Perales • 10 Apr 2019
EBMT 2019
Hodgkin Lymphoma Lymphoma Rituximab

Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the current status of allogenic hematopoietic stem cell transplantation in Hodgkin lymphoma. Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Dr Perales reports that prior checkpoint inhibitor therapy may be advantageous to patients undergoing transplantation.

More from Miguel-Angel Perales

2:53
The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts
Miguel-Angel Perales • 28 Oct 2022
1:53
Prolymphocytes as a promising GvHD prophylaxis
Miguel-Angel Perales • 28 Oct 2022
1:42
Transplantation and cell therapy highlights at COSTEM 2022
Miguel-Angel Perales • 28 Oct 2022
1:17
The impact of CAR-T therapy in the second-line setting in lymphoma
Miguel-Angel Perales • 28 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals